Abridge
Machine learning technology that powers ability to highlight key points and integrate insights that help people understand their care.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
N/A | Seed | ||
N/A | Seed | ||
N/A | Early VC | ||
N/A | Seed | ||
$15.0m | Series A | ||
* | $12.5m Valuation: $75.0m | Series A | |
* | N/A | Early VC | |
$30.0m | Series B | ||
* | $150m Valuation: $850m | Series C | |
* | $250m Valuation: $2.8b | Series D | |
$300m Valuation: $5.3b | Series E | ||
| Total Funding | $757m | ||
| USD | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 4 % | 15 % | 158 % | 525 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Dealroom estimates
Related Content
Abridge operates in the healthcare technology sector, offering an AI-powered platform designed to transform medical conversations into actionable clinical documentation. The company serves healthcare providers, payers, and pharmaceutical companies, aiming to enhance patient care and provider efficiency. Abridge's core product allows clinicians to record patient visits, which are then converted into structured clinical documents. This process helps healthcare professionals save time on documentation and focus more on patient care. The business model is likely subscription-based, targeting healthcare institutions that benefit from streamlined documentation processes and improved patient outcomes. Revenue is generated through subscriptions and possibly partnerships with healthcare organizations.
Keywords: AI-powered, healthcare technology, clinical documentation, patient care, provider efficiency, medical conversations, structured documents, subscription-based, healthcare providers, pharmaceutical companies.